X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22) 22
oncology (18) 18
adult (11) 11
male (11) 11
female (9) 9
middle aged (9) 9
aged (8) 8
antineoplastic agents - therapeutic use (8) 8
pharmacology & pharmacy (8) 8
pharmacokinetics (7) 7
animals (6) 6
camptothecin - analogs & derivatives (6) 6
camptothecin - therapeutic use (6) 6
topotecan (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
drug administration schedule (4) 4
irinotecan (4) 4
neoplasms - drug therapy (4) 4
paclitaxel (4) 4
treatment outcome (4) 4
administration, oral (3) 3
antineoplastic agents - pharmacology (3) 3
antitumor-activity (3) 3
camptothecin - pharmacokinetics (3) 3
camptothecin - pharmacology (3) 3
camptothecin - toxicity (3) 3
clinical trials as topic (3) 3
cross-over studies (3) 3
dose-response relationship, drug (3) 3
efficacy (3) 3
enzyme inhibitors - therapeutic use (3) 3
hydrocortisone - therapeutic use (3) 3
index medicus (3) 3
phase-i (3) 3
phenylurea compounds - administration & dosage (3) 3
prostatic neoplasms - drug therapy (3) 3
protein-tyrosine kinases - antagonists & inhibitors (3) 3
quinolines - administration & dosage (3) 3
receptor, erbb-2 - antagonists & inhibitors (3) 3
suramin - therapeutic use (3) 3
adenocarcinoma - drug therapy (2) 2
aged, 80 and over (2) 2
alkaloids - adverse effects (2) 2
alkaloids - therapeutic use (2) 2
angiogenesis inhibitors - administration & dosage (2) 2
anti-inflammatory agents - therapeutic use (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - pharmacokinetics (2) 2
antineoplastic agents, phytogenic - adverse effects (2) 2
antineoplastic agents, phytogenic - therapeutic use (2) 2
antineoplastic agents, phytogenic - toxicity (2) 2
av-951 (2) 2
breast neoplasms - drug therapy (2) 2
camptothecin (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - adverse effects (2) 2
cancer chemotherapy (2) 2
carcinoma, renal cell - drug therapy (2) 2
carcinoma, renal cell - mortality (2) 2
cells (2) 2
chemotherapy (2) 2
combined modality therapy (2) 2
confidence intervals (2) 2
cytochromes p450 (2) 2
disease-free survival (2) 2
double-blind method (2) 2
drug interaction (2) 2
drug screening assays, antitumor (2) 2
hamster ovary cells (2) 2
hematology, oncology and palliative medicine (2) 2
human breast-cancer (2) 2
infusions, intravenous (2) 2
inhibitor (2) 2
interferon-alpha (2) 2
irreversible inhibitors (2) 2
kaplan-meier estimate (2) 2
kidney neoplasms - drug therapy (2) 2
kidney neoplasms - mortality (2) 2
liver - drug effects (2) 2
maximum tolerated dose (2) 2
metabolic clearance rate (2) 2
neoplasm metastasis (2) 2
neoplasm staging (2) 2
pain - drug therapy (2) 2
phenylurea compounds - adverse effects (2) 2
prospective studies (2) 2
prostatic neoplasms - pathology (2) 2
protein kinase inhibitors - administration & dosage (2) 2
quality-of-life (2) 2
quinolines - adverse effects (2) 2
receptor (2) 2
reference values (2) 2
saccharomyces-cerevisiae (2) 2
safety (2) 2
solid tumors (2) 2
sorafenib (2) 2
sunitinib (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Ou, S. I and Camidge, D. R and Engelman, J and Clark, J and Tye, L and Wilner, K and Stephenson, P and Varella-Garcia, M and Iafrate, A and Shaw, A. T and Hainaut, P and Ma, X and Lacas, B and Tsao, M and Douillard, J and Rousseau, V and Dunant, A and Seymour, L and Filipits, M and Graziano, S and He, J and Yang, H and Deng, Q and He, P and Jiang, J and Zhao, M and Gu, X and Zheng, L and Pang, H and Zhou, J. X and Reinmuth, N and Scherer, S. J and Penzel, R and Schnabel, P and Meister, M and Kiemle-Kallee, J and Reuss, A and Fischer, J. R and Wolf, M and Thomas, M and von Laffert, M and Berg, E and Lenze, D and Lohneis, P and Hummel, M and Dietel, M and Han, X and Ma, L and Liu, Y and Zhang, N. N and Li, D and Shi, Y and Furugaki, K and Iwai, T and Moriya, Y and Fujimoto-Ouchi, K and Mok, T. S. K and Park, K and Geater, S. L and Agarwal, S and Han, M and Credi, M and McKee, K and Kuriyama, N and Slichenmyer, W and Tan, E. H and Greillier, L and Martel-Lafay, I and Arpin, D and Pourel, N and Chabaud, S and Lamy, R and Madroszyk, A and Fournel, P and Strom, H. H and Sundstrom, S and Helbekkmo, N and Bremnes, R and Aasebo, U and van Elmpt, W and Ollers, M and Dingemans, A. C and Lambin, P and De Ruysscher, D and Topkan, E and Parlak, C and Topuk, S and Ozyilkan, O and Uyterlinde, W and Vincent, A. D and Belderbos, J and Korse, T and Baas, P and van den Heuvel, M and Satouchi, M and Chiba, Y and Yamamoto, N and Nishimura, Y and Tsujino, K and Fujisaka, Y and ... and on behalf of The Mar-LC Collaborative Group
Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue suppl 9, pp. ix389 - ix399
Journal Article
Seminars in Oncology, ISSN 0093-7754, 2001, Volume 28, Issue 5, pp. 80 - 85
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 13, pp. 2841 - 2850
Abstract Background Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, with a... 
Hematology, Oncology and Palliative Medicine | Temsirolimus | Maximum tolerated dose | Dose escalation | Pharmacokinetics | Tivozanib | Renal cell carcinoma | TARGETED THERAPY | SOLID TUMORS | EVEROLIMUS | ANTITUMOR ACTIVITIES | INTERFERON-ALPHA | RECEPTOR TYROSINE KINASES | ONCOLOGY | SUNITINIB | INHIBITOR | III TRIAL | ENDOTHELIAL GROWTH-FACTOR | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Quinolines - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Angiogenesis Inhibitors - administration & dosage | Time Factors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Sirolimus - analogs & derivatives | Drug Administration Schedule | Administration, Oral | Kaplan-Meier Estimate | Treatment Outcome | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Administration, Intravenous | Maximum Tolerated Dose | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Kidney Neoplasms - enzymology | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Medicine, Experimental | Medical research | Care and treatment | Carcinoma, Renal cell | Antineoplastic agents | Index Medicus
Journal Article
SEMINARS IN ONCOLOGY, ISSN 0093-7754, 10/2001, Volume 28, Issue 5, pp. 80 - 85
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1678 - 1685
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2012, Volume 30, Issue 31, pp. 3902 - 3902
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2011, Volume 29, Issue 15_suppl, pp. 4550 - 4550
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15_suppl, pp. e13564 - e13564
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15_suppl, pp. TPS169 - TPS169
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2011, Volume 29, Issue 15_suppl, pp. 7571 - 7571
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2011, Volume 47, pp. S21 - S22
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 11/2011, Volume 10, Issue Supplement 1, pp. C121 - C121
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.